Glykit-M 3 Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 3mg and Metformin 1000mg, formulated for sustained release to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release formulation ensures a gradual release of active ingredients, promoting better tolerability and adherence by minimizing gastrointestinal side effects commonly associated with metformin. Glykit-M 3 Forte is indicated as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and patient tolerance. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. This combination therapy should be used under medical supervision, with attention to potential hypoglycemia risk due to glimepiride and contraindications related to metformin use.